9.91
-0.15
(-1.44%)
As of 3:08:16 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 3 | 4 |
| Avg. Estimate | -0.16 | -0.25 | -0.57 | -0.92 |
| Low Estimate | -0.21 | -0.27 | -0.76 | -1.29 |
| High Estimate | -0.11 | -0.22 | -0.3 | -0.67 |
| Year Ago EPS | -0.23 | -0.18 | -1.02 | -0.57 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 4 | 6 | 7 |
| Avg. Estimate | 62.17M | 5.19M | 141.31M | 25.1M |
| Low Estimate | 6M | 1.78M | 74.6M | -- |
| High Estimate | 186M | 8M | 263M | 60.3M |
| Year Ago Sales | 28.93M | 55.13M | 124.8M | 141.31M |
| Sales Growth (year/est) | 114.89% | -90.58% | 13.24% | -82.24% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.29 | -0.24 | -0.24 | -0.24 |
| EPS Actual | -0.23 | -0.18 | -0.3 | -0.2 |
| Difference | 0.06 | 0.06 | -0.06 | 0.04 |
| Surprise % | 20.11% | 25.67% | -23.75% | 17.17% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.25 | -0.57 | -0.92 |
| 7 Days Ago | -0.22 | -0.25 | -0.63 | -1.04 |
| 30 Days Ago | -0.21 | -0.22 | -0.85 | -0.99 |
| 60 Days Ago | -0.21 | -0.22 | -0.85 | -0.99 |
| 90 Days Ago | -0.19 | -0.22 | -0.84 | -0.94 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | -- | 1 | 2 |
| Up Last 30 Days | 2 | -- | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ROIV | 30.30% | -37.33% | 44.18% | -61.84% |
| S&P 500 | 6.79% | 5.59% | 9.06% | 14.11% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/11/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 9/19/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/19/2024 |
| Maintains | B of A Securities: Neutral to Neutral | 9/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/11/2024 |
Related Tickers
IMVT Immunovant, Inc.
14.56
-5.85%
ABUS Arbutus Biopharma Corporation
3.0000
-5.06%
INBX Inhibrx Biosciences, Inc.
11.46
-2.80%
BBIO BridgeBio Pharma, Inc.
33.15
-3.18%
CYTK Cytokinetics, Incorporated
38.46
-0.26%
TLX Telix Pharmaceuticals Limited
16.80
-0.12%
RPRX Royalty Pharma plc
32.11
-1.06%
GMAB Genmab A/S
19.44
-0.38%
NUVL Nuvalent, Inc.
69.40
-1.96%
ASND Ascendis Pharma A/S
155.92
+1.30%